Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.66 |
| ▸ | LTA4H | P09960 | 4/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | FCER2 | P06734 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6447736 | 1.00 | MME (0.66) | MMELTA4HMMP1FCER2ANPEP | |
| SCHEMBL6447730 | 1.00 | MME (0.66) | MMELTA4HMMP1FCER2ANPEP | |
| SCHEMBL6447498 | 0.92 | MME (0.62) | MMELTA4HMMP1FCER2 | |
| SCHEMBL6447267 | 0.92 | MME (0.62) | MMELTA4HMMP1FCER2 | |
| SCHEMBL6447264 | 0.92 | MME (0.62) | MMELTA4HMMP1FCER2 | |
| SCHEMBL6447064 | 0.85 | MME (0.54) | MMELTA4HMMP1ECE1 | |
| SCHEMBL6447062 | 0.85 | MME (0.54) | MMELTA4HMMP1ECE1 | |
| SCHEMBL6447060 | 0.85 | MME (0.54) | MMELTA4HMMP1ECE1 | |
| SCHEMBL9727512 | 0.81 | MME (0.47) | MMELTA4H | |
| SCHEMBL9222947 | 0.80 | CPA1 (0.71) | MMEANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | MME 11/4885LTA4H 1142/4885MMP1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.